Fundraising Fox
Oncotarget
Founded 2010 · 6 employees on LinkedIn · 1 known investors
Find your way into Oncotarget
Sign up to see every warm intro you have to Oncotarget
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oncotarget team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oncotarget is a peer-reviewed academic journal publishing oncology and cancer research papers, indexed in databases such as PubMed, MEDLINE, and Scopus. It is operated by Rapamycin Press LLC (dba Impact Journals) and serves researchers and investigators in cancer research and medicine.
Founders & leadership
WS
Wafik S. El-DeiryCo-Editor-in-ChiefHe is the Mencoff Family Endowed University Professor of Medical Science and a tenured Professor of Pathology and Laboratory Medicine at Brown University, where he founded and led the Legorreta Cancer Center and the Joint Program in Cancer Biology and now serves as Director Emeritus of the Cancer Center. He is also pursuing a Physician MBA at the Kelley School of Business, with an expected graduation in 2028.
Investors · 1
Frequently asked questions
- What does Oncotarget do?
- Oncotarget is a peer-reviewed academic journal publishing oncology and cancer research papers, indexed in databases such as PubMed, MEDLINE, and Scopus. It is operated by Rapamycin Press LLC (dba Impact Journals) and serves researchers and investigators in cancer research and medicine.
- Who are Oncotarget's investors?
- Oncotarget's investors include Compound.